SCHEMBL16212948

SCHEMBL16212948

COC(=O)c1csc(C(=O)CCN2CCOCC2)c1C

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
EED O75530 1/20 0.46
RBBP4 Q09028 1/20 0.46
SUZ12 Q15022 1/20 0.46
EZH2 Q15910 1/20 0.46
AEBP2 Q6ZN18 1/20 0.46
ALDH1A1 P00352 9/20 0.44
KMT2A Q03164 8/20 0.44
MAPT P10636 5/20 0.44
MAOA P21397 1/20 0.43
MAOB P27338 1/20 0.43
RAB9A P51151 1/20 0.43
POLB P06746 2/20 0.42
TSHR P16473 1/20 0.42
MEN1 O00255 2/20 0.42
KDM4E B2RXH2 1/20 0.42
MAPK1 P28482 1/20 0.42
L3MBTL1 Q9Y468 1/20 0.42
LMNA P02545 2/20 0.41
MPI P34949 1/20 0.41
THRB P10828 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL16212561 0.87 EED (0.59) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16212563 0.87 EED (0.59) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL17670064 0.86 KMT2A (0.50) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16212750 0.81 CNR1 (0.43) ALDH1A1KMT2APOLBTSHRMEN1
SCHEMBL16212766 0.81 EED (0.46) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL19460293 0.81 KMT2A (0.44) ALDH1A1KMT2AMAPTMAOAMAOB
SCHEMBL28054865 0.79 KMT2A (0.44) ALDH1A1KMT2AMAPTMAOAMAOB
SCHEMBL28054866 0.77 KMT2A (0.51) ALDH1A1KMT2AMAPTRAB9AMEN1
SCHEMBL18415992 0.76 GSK3B (0.49) EEDRBBP4SUZ12EZH2AEBP2
SCHEMBL16212553 0.75 GSK3B (0.55) EEDRBBP4SUZ12EZH2AEBP2

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2991980-B1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE IP NO 2 LTD (GB) 2019-01-02 EP disclosed
US-9790212-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-10-17 US disclosed
US-9790212-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-10-17 US disclosed
US-9790212-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2017-10-17 US disclosed
US-20170029412-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-02-02 US disclosed
US-20170029412-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-02-02 US disclosed
US-20170029412-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2017-02-02 US disclosed
US-9505745-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2016-11-29 US disclosed
US-9505745-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2016-11-29 US disclosed
US-9505745-B2 Enhancer of zeste homolog 2 inhibitors GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED (GB) 2016-11-29 US disclosed
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-04-14 US disclosed
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-04-14 US disclosed
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2016-04-14 US disclosed
EP-2991980-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS Glaxosmithkline Intellectual Property (No. 2) Limited (GB) 2016-03-09 EP disclosed
WO-2014177982-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO.2) LIMITED (GB) 2014-11-06 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160102083-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 EED 5/4885RBBP4 190/4885SUZ12 4/4885
US-20170029412-A1 ENHANCER OF ZESTE HOMOLOG 2 INHIBITORS EZH2, BMI1, EZH1 EED 5/4885RBBP4 190/4885SUZ12 4/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.